newsfilter
← Latest News
Business Wire·

Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 Adherence

Average Total Weight Loss of 23% With 14% Increase in Lean Body Mass After 12 Months All patients remained adherent to tirzepatide for the duration of the study Allurion Technologies, Inc. ("Allurion" or the